DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for choroid plexus carcinoma — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChoroid plexus carcinoma maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for choroid plexus carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
isocitrate dehydrogenase (NADP(+)) 2 (IDH2) — IDH2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ndpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5I96 · 1.55 Å · ligand NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NDP). Experimental structure, not a prediction.
What the evidence adds up to
In a French series of 22 children with choroid plexus carcinoma registered between 1984 and 1995, the 5-year survival rate was 26%. The only factor that correlated with survival was the extent of surgery: patients who had total or gross total resection had an 86% survival rate. All but one patient with incomplete surgery had tumour recurrence within 2 to 23 months. Survival did not correlate with age, sex, delay to diagnosis, tumour location, tumour volume, or response to postoperative treatment. Nineteen children received postoperative treatment, with chemotherapy in 17 and radiotherapy in 2; two responding patients underwent high-dose chemotherapy with stem cell rescue. The authors concluded that aggressive surgical resection is necessary for survival and that "second look" surgery should be considered for patients with incomplete resection.
A single case report from 1994 describes a girl diagnosed at age 3 months who was apparently cured with minimal surgical resection, chemotherapy, and delayed irradiation. At age 8 she was well, with minor psychomotor retardation and growth hormone deficiency as the only sequelae. A 2021 single-institutional series covering 8 decades (1939–2020) included 59 children with choroid plexus tumours, but only 7 of those had atypical choroid plexus papilloma and none of the reported survival data specifically address choroid plexus carcinoma. In that series, low-grade tumours (papillomas) had 100% observed 5-year and 10-year survival after gross total resection alone, with 96% of survivors achieving a Barthel Index score of 100. Recurrences in low-grade tumours were uncommon (8.7%) and appeared within the first few years after primary surgery.
A 2018 review states that maximal surgical resection remains the main therapeutic strategy for choroid plexus carcinoma and that the clinical efficacy of postoperative adjuvant therapies remains controversial. It notes that recent studies suggest postoperative combination of radiotherapy and chemotherapy may enhance prognosis and prolong survival for patients undergoing sub-radical resection, but provides no specific survival numbers or sample sizes. A 2001 case report describes a 53-year-old male with a lateral ventricle choroid plexus carcinoma and CSF metastases treated with total tumour excision followed by post-operative craniospinal irradiation, but offers no generalisable outcome data.
What is still missing: prospective, multicentre trials large enough to test whether any chemotherapy or radiotherapy regimen improves survival beyond what can be achieved by complete surgical resection alone. The rarity of the tumour makes such trials difficult to fund and accrue. Patient stratification by extent of resection is essential but not yet standardised across centres.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurosurgery · 1998 · 197 citations
Choroid Plexus Carcinomas in Childhood: Clinical Features and Prognostic Factors
AbstractOBJECTIVE: Choroid plexus carcinomas are rare tumors with dismal prognosis. The role of surgery has been well established, but the benefit of either chemotherapy or radiotherapy remains controversial. To determine prognostic factors and effects of different therapeutic modalities on the outcome, we have reviewed the French experience of choroid plexus carcinoma. METHODS: Twenty-two children were registered in the Société Française d'Oncologie Pédiatrique between 1984 and 1995. All these children underwent surgical resection of the primary tumor. The intent of postoperative treatment was to delay or to avoid radiation therapy. Nineteen children received postoperative treatment, with chemotherapy in 17 and radiation therapy in 2. Two responding patients underwent high-dose chemotherapy with stem cell rescue. RESULTS: The 5-year survival rate was 26%. The sole relevant prognostic factor was the extent of surgery. Patients with total or gross total resection had a 86% survival rate. Survival did not correlate with age, sex, delay between first appearance of symptoms and diagnosis, location of the primary tumor, tumor volume, or response to postoperative treatment. All but one patient with incomplete surgery had tumor recurrence within 2 to 23 months. CONCLUSION: Choroid plexus carcinoma has a very poor prognosis when surgery is incomplete. Aggressive surgical resection of the tumor is necessary for survival. Although chemotherapy gives promising responses, local control remains the main challenge, and "second look" surgery has to be considered for patients with incomplete resection.
Medical and Pediatric Oncology · 1994 · 22 citations
Choroid plexus carcinoma: Report of one case with favourable response to treatment
AbstractChoroid plexus carcinoma (CPC) is a rare tumor with usually severe prognosis, whose optimal treatment has not yet been established. The exact role of complete surgical resection, chemotherapy, and radiotherapy has been debated but not clarified. We report one girl with CPC diagnosed at age 3 months and apparently cured with minimal surgical resection, chemotherapy, and delayed irradiation. At the age of 8 years, she is well, with minor psychomotor retardation and growth hormone deficiency as the only sequelae.
World Neurosurgery · 2021 · 9 citations · open access
Choroid Plexus Tumors in Children: Long-Term Follow-Up of Consecutive Single-Institutional Series of 59 Patients Treated over a Period of 8 Decades (1939–2020)
AbstractOBJECTIVE: To present long-term follow-up of a consecutive single-institutional series of patients treated for choroid plexus tumors over 8 decades. METHODS: From 1939 to 2020, 59 children were treated for choroid plexus tumors. Median age at diagnosis was 1.7 years. RESULTS: Gross total resection was achieved in 51 patients (86%). Ten patients (17%) underwent >1 resection. During the first 4 decades of the study (1939-1979), 14 patients with plexus papillomas were treated. Operative mortality was 50%, with 6 of the remaining 7 patients experiencing excellent survival with follow-up periods of 41-81 years. In the last 4 decades (1980-2020), 38 patients had low-grade tumors, and all were alive at the latest follow-up (range, 0.5-39 years). Observed 5-year survival in this subgroup was 100% (n = 30), as was observed 10-year survival (n = 26). One of 7 (14%) patients with atypical choroid plexus papilloma and 3 of 31 patients (10%) with choroid plexus papilloma underwent a second resection owing to recurrent tumor. At last follow-up, 47 patients (80%) were alive; 45 (96%) had a Barthel Index score of 100 and 2 had a Barthel Index score of 50. Today 25 patients are adults (20-59 years old); 17 work full-time, 4 work part-time, and 4 are unable to work. CONCLUSIONS: Low-grade choroid plexus tumors can be cured with gross total resection alone, with excellent long-term survival and functionality. The vast majority of survivors live independently as adults and work full-time. Recurrences are uncommon (8.7%), appear within the first few years after primary surgery, and can be treated with repeat resections.
Current status and research progress on diagnosis and treatment of choroid plexus carcinoma
AbstractChoroid plexus carcinoma is a relatively rare primary intracranial malignant tumor which is derived from the choroid plexus epithelium. It is classified as World Health Organization (WHO) grade Ⅲ and mainly occurs in children. Currently, maximal surgical resection is still the main therapeutic strategy. The clinical efficacy of postoperative adjuvant therapies remains controversial. Recent studies have promoted that postoperative combination of radiotherapy and chemotherapy can enhance the clinical prognosis and prolong the survival time for choroid plexus carcinoma patients undergoing sub-radical resection. In this review, relevant articles published in the recent 15 years were retrieved to summarize the current status and research progress on the diagnosis and treatment of choroid plexus carcinoma.
Key words:
Choroid plexus carcinoma; Diagnosis; Treatment; Progress
Choroid Plexus Carcinoma of the Lateral Ventricle: Case Report and Review
AbstractPrimary carcinoma of choroid plexus are rare and found most frequently in children than in adults. In children, the choroid plexus carcinoma are located predominantly in the lateral ventricles, while adults in the fourth ventricle. This report is about a 53 year old male with primary carcinoma located in the lateral ventricle with CSF metastases, which was treated with total tumor excision of choroids plexus followed by post-operative cranial spinal irradiation. This paper aims at the possibilities and limitations of the treatment of primary carcinoma of choroids plexus.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
